Box 2
Contains 32 Results:
Clinical Evaluation of Iridium 191m: annual reports, 1992-1997
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Clinical Evaluation of Iridium 191m: protocol amendment, 1993-1995
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Clinical Evaluation of Iridium 191m, Phase IIIa-b: amendment, appendices, reports, 1993- 1995
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Clinical Evaluation of Iridium 191m, Phase II: amendment, appendices, [c1994]
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Clinical Investigation of Iridium 191m for the Determination of Ventricular Ejection Fraction: Phase II protocol, 1988-2003
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Copper 62 Radiopharmeceutical for the Evaluation of Multidrug Resistance in Tumors: proposal, 1997
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Development of a New Osmium 191 - Iridium 191m Radionuclide Generator: proposal, reports, 1986-1988, undated
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Evaluation of Computerized System for Reducing Injection Delay in Ictal SPECT Studies: applications, forms, 2005
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Functional Imaging of Multidrug Resistance in Breast Cancer with PET: proposal, 1999
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results
Hodgkin's Research Study, Boston Children's Heart Foundation: billing record, 1996
Consists of documentation relating to studies in 51Cr-EDTA, Copper 62 Radiopharmeceuticals, Iridium-191m, Osmium-191, Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT). This is concerned mainly with funding acquisition, protocol development, and reporting to funders, though some of the material relates to human study patient consent, and reporting on study results